Early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up : 2nd ESMO Consensus Conference on Lung Cancer.
Fiche du document
2014
- doi: 10.1093/annonc/mdu089
- issn: 0923-7534
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1093/annonc/mdu089
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/24562446
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1569-8041
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_45510A1834466
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
Lung cancer illnessCiter ce document
J. Vansteenkiste et al., « Early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up : 2nd ESMO Consensus Conference on Lung Cancer. », Serveur académique Lausannois, ID : 10.1093/annonc/mdu089
Métriques
Partage / Export
Résumé
To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines in advanced disease, early-stage disease and locally advanced disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on early-stage disease.